Patrick Bursey News Today

SAN DIEGO, March 02, 2023 -- Cidara Therapeutics, Inc. , a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious... | March 2, 2023

Canary Medical, a medical data company focused on the development and commercialization of its patented implantable sensor technology and data management

VANCOUVER, British Columbia and CARLSBAD, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Canary Medical, a medical data company focused on the development and...

REN-001 IND submission planned for the second half of 2022Data from pilot pig study showing successful cardiac transduction with REN-001 delivered via low-dose retrograde coronary sinus infusion published in Journal of the American College of Cardiology: Basic to Translational ScienceCAMBRIDGE, Mass.--(BUSINESS WIRE...

Research collaboration with the University of Utah's Nora Eccles Harrison Cardiovascular Research and Training Institute expands pipeline with the addition of an AAV gene therapy program for multiple genetic segments of arrhythmogenic cardiomyopathyCAMBRIDGE, Mass.--(BUSINESS WIRE)--Renovacor, Inc. (NYSE: RCOR), a b...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

In February, the FDA declined to approve the companys new drug application as it was presented and asked the company to submit additional evidence of effectiveness for epidermolysis bullosa (EB).

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics...

For Trade and Medical Media Only Rezafungin is a next-generation once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as invasive candidiasis